ArticleFrontiers in neurology2026
A novel integrated inflammatory-metabolic indicator as a potential predictor of obstructive sleep apnea: evidence from a clinical cohort and validation in the US National Health and Nutrition Examination Survey.
Article in Frontiers in neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Obstructive sleep apnea (OSA) is a prevalent sleep-disordered breathing condition closely associated with cardiovascular and metabolic risks. The current diagnostic gold standard, polysomnography, faces accessibility limitations, necessitating the development of simplified screening tools. Integrating multi-pathway information from hematological biomarkers may offer novel approaches. Objective: To systematically evaluate the association between multiple novel inflammatory-metabolic composite indices and OSA risk, and validate their stability across different populations. Methods: A two-stage cross-sectional study design was employed. Stage one utilized a clinical cohort from Chengdu Third People's Hospital, China ( Results: After adjusting for demographics, lifestyle factors, and clinical comorbidities, multiple indicators were independently associated with OSA risk. Within the clinical cohort, AIP, UHR, and RC/HDL demonstrated the most robust associations; in the NHANES cohort, CMI (AUC = 0.621), UHR (AUC = 0.613), AIP, and RC/HDL (both AUC = 0.602) exhibited favorable predictive performance. Subgroup analyses revealed that the predictive value of these markers was particularly pronounced in individuals aged≤60 years, females, non-obese individuals, and those without underlying conditions (hypertension, diabetes, cardiovascular disease). Conclusion: This two-phase study identified several readily available inflammatory-metabolic composite indices (e.g., MHR, AIP, CMI) as independently associated with OSA risk; these markers demonstrate potential as adjunctive tools for assessing OSA risk. Their predictive efficacy exhibits population heterogeneity, necessitating consideration of individual characteristics in clinical application. Prospective studies are required to further validate their causal associations and clinical utility.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.